Cytodyn Inc (CYDY)

[Cindylou822]

Remember, the survival percentage for leronlimab was always excellent. The problem was a lack of distinction from placebo. If it had been a low survival rate, then it would have been a desperate measure to avoid futility, but, then it would have been wrong to continue enrollment. that 75% cutoff data and longer follow up to give placebo patients more time to die, sadly, would have either pushed them over the edge to statistical significance or given them enough hypothesis generating information to go back to the FDA and add an arm to the study to prove their MOA was the reason for response